CoChat

Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Open access
Aarntzen, Erik H. J. G., Schreibelt, Gerty, Bol, Kalijn, Lesterhuis, W. Joost, Croockewit, Alexandra J., de Wilt, Johannes H. W., van Rossum, Michelle M., Blokx, Willeke A. M., Jacobs, Joannes F. M., Duiveman-de Boer, Tjitske, Schuurhuis, Danita H., Mus, Roel, Thielemans, Kris, de Vries, I. Jolanda M., Figdor, Carl G., Punt, Cornelis J. A., Adema, Gosse J. · 2012 · Clinical Cancer Research
Cited by 103

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Electroporation of dendritic cells (DC) with mRNA encoding tumor-associated antigens (TAA) has multiple advantages compared to peptide loading. We investigated the immunologic and clinical responses to vaccination with mRNA-electroporated DC in stage III and IV melanoma patients. Experimental design: Twenty-six stage III HLA*02:01 melanoma patients scheduled for radical lymph node dissection (stage III) and 19 melanoma patients with irresectable locoregional or distant metastatic disease (referred to as stage IV) were included. Monocyte-derived DC, electroporated with mRNA encoding gp100 and tyrosinase, were pulsed with keyhole limpet hemocyanin and administered intranodally. TAA-specific T-cell responses were monitored in blood and skin-test infiltrating lymphocyte (SKIL) cultures. Results: Comparable numbers of vaccine-induced CD8+ and/or CD4+ TAA-specific T-cell responses were detected in SKIL cultures; 17/26 stage III patients and 11/19 stage IV patients. Strikingly, in this population, TAA-specific CD8+ T cells that recognize multiple epitopes and produce elevated levels of IFNγ upon antigenic challenge in vitro, were significantly more often observed in stage III patients; 15/17 versus 3/11 stage IV patients, P = 0.0033. In stage IV patients, one mixed and one partial response were documented. The presence or absence of IFNγ-producing TAA-specific CD8+ T cells in stage IV patients was associated with marked difference in median overall survival of 24.1 months versus 11.0 months, respectively. Conclusion: Vaccination with mRNA-electroporated DC induces a broad repertoire of IFNγ producing TAA-specific CD8+ and CD4+ T-cell responses, particularly in stage III melanoma patients. Clin Cancer Res; 18(19); 5460–70. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-3368

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 103

Metadata

Authors
Aarntzen, E. H. J. G., Schreibelt, G., Bol, K., Lesterhuis, W. J., Croockewit, A. J., de Wilt, J. H. W., van Rossum, M. M., Blokx, W. A. M., Jacobs, J. F. M., Duiveman-de Boer, T., Schuurhuis, D. H., Mus, R., Thielemans, K., de Vries, I. J. M., Figdor, C. G., Punt, C. J. A., & Adema, G. J.
Venue
Clinical Cancer Research
Published
2012-09-30
Volume
18
Issue
19
Pages
5460-5470
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2104401785
Cited by
103
References
5
FWCI
3.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-3368
The paper
Aarntzen, E. H. J. G., Schreibelt, G., Bol, K., Lesterhuis, W. J., Croockewit, A. J., de Wilt, J. H. W., van Rossum, M. M., Blokx, W. A. M., Jacobs, J. F. M., Duiveman-de Boer, T., Schuurhuis, D. H., Mus, R., Thielemans, K., de Vries, I. J. M., Figdor, C. G., Punt, C. J. A., & Adema, G. J. (2012). Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-3368

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.